Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.

This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.

[1]  Vasco Filipe,et al.  Mass Spectrometric Analysis of Intact Human Monoclonal Antibody Aggregates Fractionated by Size-Exclusion Chromatography , 2010, Pharmaceutical Research.

[2]  D. Ren,et al.  Protein isoaspartate methyltransferase-mediated 18O-labeling of isoaspartic acid for mass spectrometry analysis. , 2012, Analytical chemistry.

[3]  M. Sliwkowski,et al.  Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer , 2010 .

[4]  A. Beck,et al.  World Antibody Drug Conjugate Summit Europe , 2011, mAbs.

[5]  T. Wurch,et al.  Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.

[6]  L. Khawli,et al.  Charge variants in IgG1 , 2010, mAbs.

[7]  Ya-jun Guo,et al.  Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors , 2011, mAbs.

[8]  E. Ezan,et al.  Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. , 2008, Analytical chemistry.

[9]  M. Wadhwa,et al.  Biosimilars—why terminology matters , 2011, Nature Biotechnology.

[10]  M. Mccamish,et al.  Worldwide experience with biosimilar development , 2011, mAbs.

[11]  Hendrik Neubert,et al.  Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. , 2008, Analytical chemistry.

[12]  Olivier Heudi,et al.  Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.

[13]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[14]  Zhongqi Zhang,et al.  Mass spectrometry for structural characterization of therapeutic antibodies. , 2009, Mass spectrometry reviews.

[15]  D. Michels,et al.  Identification of codon-specific serine to asparagine mistranslation in recombinant monoclonal antibodies by high-resolution mass spectrometry. , 2009, Analytical chemistry.

[16]  J. Reichert,et al.  European Medicines Agency workshop on biosimilar monoclonal antibodies , 2009, mAbs.

[17]  J. Garin,et al.  Isotope dilution strategies for absolute quantitative proteomics. , 2009, Journal of proteomics.

[18]  S. Sanglier-Cianférani,et al.  Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS. , 2009, Analytical chemistry.

[19]  Alain Beck,et al.  Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. , 2009, Analytical biochemistry.

[20]  S. Berkowitz,et al.  Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. , 2009, Analytical chemistry.

[21]  Franklin Peale,et al.  Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.

[22]  Alain Van Dorsselaer,et al.  Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  P. Schnier,et al.  Resolving disulfide structural isoforms of IgG2 monoclonal antibodies by ion mobility mass spectrometry. , 2010, Analytical chemistry.

[24]  M. Eisenstein.  Something new under the skin , 2011, Nature Biotechnology.

[25]  V. Katta,et al.  Structural characterization of intact antibodies by high-resolution LTQ Orbitrap mass spectrometry. , 2009, Journal of mass spectrometry : JMS.

[26]  Teresa Mitchell,et al.  Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study , 2011, mAbs.

[27]  W. Hancock,et al.  Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation. , 2009, Analytical chemistry.

[28]  C. Damen,et al.  The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum. , 2009, Journal of pharmaceutical and biomedical analysis.

[29]  P. Bondarenko,et al.  Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-orbitrap mass spectrometer , 2009, Journal of the American Society for Mass Spectrometry.

[30]  M. Schenerman,et al.  Advances in the assessment and control of the effector functions of therapeutic antibodies , 2011, Nature Reviews Drug Discovery.

[31]  W. Hancock,et al.  Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: using LC-MS with electron transfer dissociation. , 2011, Analytical chemistry.

[32]  M. Sliwkowski,et al.  Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. , 2010, Cancer research.

[33]  T. P. Frandsen,et al.  Development of mass spectrometry based techniques for the identification and determination of compositional variability in recombinant polyclonal antibody products. , 2010, Analytical chemistry.

[34]  P. Parren,et al.  Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains , 2011, Nature Biotechnology.

[35]  P. Bondarenko,et al.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.

[36]  Darrell Ricke,et al.  Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. , 2008, Analytical chemistry.

[37]  G. A. Lazar,et al.  Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.

[38]  F. Wurm,et al.  Structural analysis of intact monoclonal antibodies by electron transfer dissociation mass spectrometry. , 2011, Analytical chemistry.

[39]  Jason C Rouse,et al.  Unit mass baseline resolution for an intact 148 kDa therapeutic monoclonal antibody by Fourier transform ion cyclotron resonance mass spectrometry. , 2011, Analytical chemistry.

[40]  A. Beck.  Biosimilar, biobetter and next generation therapeutic antibodies , 2011, mAbs.

[41]  Janice M Reichert,et al.  Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies , 2011, mAbs.

[42]  Detlev Suckau,et al.  Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. , 2010, Journal of proteome research.

[43]  Alain Beck,et al.  GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins , 2010, Expert opinion on drug discovery.

[44]  Martin Schiestl,et al.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals , 2011, Nature Biotechnology.

[45]  Alain Van Dorsselaer,et al.  The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[46]  John R. Engen,et al.  Analysis of protein conformation and dynamics by hydrogen/deuterium exchange MS. , 2009, Analytical chemistry.

[47]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[48]  S. Tuske,et al.  Epitope mapping by amide hydrogen/deuterium exchange coupled with immobilization of antibody, on-line proteolysis, liquid chromatography and mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[49]  T. Wurch,et al.  6th Annual European Antibody Congress 2010 , 2011, mAbs.

[50]  C. Schneider,et al.  Toward biosimilar monoclonal antibodies , 2008, Nature Biotechnology.